Dimer formation may provide additional stabilization of the NO complex in the insect salivary gland, where storage is required, by protecting the NO moiety from escape or reaction with other molecules.
The decreased π-accepting ability of the NO moiety in 2 does not favor such transitions; instead transitions from orbitals centered at the FeNO unit to the πpy orbitals of the ligand frame become more favorable and the photolability of NO is lost in 2.
Over the past few years, 'NO-releasing' NSAIDs have been developed; in these agents, an NSAID is chemically linked with a NO moiety [ 99].
Differences in S-nitrosylation (SNO), a protein modification that involves the addition of an NO moiety to protein sulfhydryl groups, have also been described [ 40, 41].
The reverse process of S-nitrosylation is termed denitrosylation and involves the release of the NO moiety from the SNO bond.
The NO-donating GC [23], Nitro-Dex, did inhibit aggregation, but this effect is clearly due to the NO moiety, which releases NO in biological fluids, and not to the GC moiety since Dex alone was ineffective.
NO is also released from some drugs, historically nitrates, but more recently other agents that have been specifically designed to contain a NO moiety, which is released enzymatically in tissues and plasma.
Moreover, in the case of TMA, Complex III rather than NDMA ultimately forms, in which the methylium cation associates with the nitrogen atom of the NO moiety in NDMA.
However, as more evidence accumulates about the possible adverse cardiovascular effects of many of the NSAIDs, the question of whether the addition of the NO moiety to a NSAID might improve the cardiovascular risk profile of patients taking chronic NSAIDs has arisen.
Protein sulfhydryl modification by oxidized NO to yield S-nitrosothiol (S-NO) moieties is widely accepted as an important regulatory mechanism.
